Literature DB >> 26284466

miRNA for diagnosis and clinical implications of human hepatocellular carcinoma.

Yurong Wang1,2, Yaping Tian1,2.   

Abstract

Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies, as a result of being asymptomatic at early stage, subsequent late clinical confirmation and poor prognosis. It is urgent to search more accurate biomarkers for diagnosing early HCC and predicting prognosis. Many factors participate in liver carcinogenesis, including dysregulation of miRNA. miRNA were endogenously expressed non-coding single-stranded small RNA with 19-25 nucleotides. Accumulating evidences have showed that miRNA from circulation and solitary tumors may be useful to classify the differentiation degree and stages of HCC, detect the hepatitis B/C virus-related HCC, and predict the survival rate after surgical resection or orthotopic liver transplantation. In this review, we summarize dysregulated miRNA, their roles in diagnosis and clinical implications of HCC.
© 2015 The Japan Society of Hepatology.

Entities:  

Keywords:  diagnosis; hepatocellular carcinoma; miRNA; prediction

Year:  2015        PMID: 26284466     DOI: 10.1111/hepr.12571

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  13 in total

1.  MicroRNAs are key regulators of hepatocellular carcinoma (HCC) cell dissemination-what we learned from microRNA-494.

Authors:  Margarita González-Vallinas; Kai Breuhahn
Journal:  Hepatobiliary Surg Nutr       Date:  2016-08       Impact factor: 7.293

2.  MTA1 modulated by miR-30e contributes to epithelial-to-mesenchymal transition in hepatocellular carcinoma through an ErbB2-dependent pathway.

Authors:  L Deng; J Tang; H Yang; C Cheng; S Lu; R Jiang; B Sun
Journal:  Oncogene       Date:  2017-03-13       Impact factor: 9.867

3.  The long non-coding RNA TP73-AS1 modulates HCC cell proliferation through miR-200a-dependent HMGB1/RAGE regulation.

Authors:  Shaling Li; Yan Huang; Yun Huang; Yongming Fu; Daolin Tang; Rui Kang; Rongrong Zhou; Xue-Gong Fan
Journal:  J Exp Clin Cancer Res       Date:  2017-04-12

4.  Knockdown of the differentially expressed gene TNFRSF12A inhibits hepatocellular carcinoma cell proliferation and migration in vitro.

Authors:  Tao Wang; Sicong Ma; Xingxing Qi; Xiaoyin Tang; Dan Cui; Zhi Wang; Jiachang Chi; Ping Li; Bo Zhai
Journal:  Mol Med Rep       Date:  2017-01-26       Impact factor: 2.952

5.  Serum exosomal microRNAs combined with alpha-fetoprotein as diagnostic markers of hepatocellular carcinoma.

Authors:  Yurong Wang; Chunyan Zhang; Pengjun Zhang; Guanghong Guo; Tao Jiang; Xiumei Zhao; Jingjing Jiang; Xueliang Huang; Hongli Tong; Yaping Tian
Journal:  Cancer Med       Date:  2018-03-23       Impact factor: 4.452

6.  The Oncogenic Role of ARG1 in Progression and Metastasis of Hepatocellular Carcinoma.

Authors:  Jia You; Wei Chen; Jing Chen; Qi Zheng; Jing Dong; Yueyong Zhu
Journal:  Biomed Res Int       Date:  2018-09-18       Impact factor: 3.411

7.  MiRNA Polymorphisms and Hepatocellular Carcinoma Susceptibility: A Systematic Review and Network Meta-Analysis.

Authors:  Qimeng Zhang; Xueying Xu; Mingcheng Wu; Tiantian Qin; Shaoning Wu; Hongbo Liu
Journal:  Front Oncol       Date:  2021-01-19       Impact factor: 6.244

8.  CircPTK2 inhibits cell cisplatin (CDDP) resistance by targeting miR-942/TRIM16 axis in non-small cell lung cancer (NSCLC).

Authors:  Yongfu Wang; Yuanlin Wu; Shaoqiang Xie
Journal:  Bioengineered       Date:  2022-02       Impact factor: 3.269

9.  Potential miRNA-target interactions for the screening of gastric carcinoma development in gastric adenoma/dysplasia.

Authors:  Yu Jin Kim; Ki-Chul Hwang; Sang Woo Kim; Yong Chan Lee
Journal:  Int J Med Sci       Date:  2018-03-14       Impact factor: 3.738

10.  miR-425-5p Acts as a Molecular Marker and Promoted Proliferation, Migration by Targeting RNF11 in Hepatocellular Carcinoma.

Authors:  Dan Rao; Songmei Guan; Junwei Huang; Qing Chang; Shigang Duan
Journal:  Biomed Res Int       Date:  2020-10-16       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.